PAVmed to Host Business Update Conference Call
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Source: PRnewswire
- Conference Details: PAVmed will host a business update conference call on March 30, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D. will discuss the company's operations and growth strategy, aiming to bolster investor confidence in future developments.
- Financial Results Discussion: CFO Dennis McGrath will present the fourth quarter 2025 financial results during the call, expected to reveal the company's performance in the medical device and digital health sectors, assisting investors in assessing market positioning.
- Webcast Availability: The conference call will be available via webcast on the company's investor relations section, ensuring global investors can access real-time updates, thereby enhancing transparency and communication efficiency.
- Replay Service: A replay of the call will be available for 30 days post-conference on the investor relations section of the website, allowing investors who missed the live event to review the content, further improving information accessibility and interaction with stakeholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LUCD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LUCD
Wall Street analysts forecast LUCD stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.070
Low
3.00
Averages
4.05
High
8.25
Current: 1.070
Low
3.00
Averages
4.05
High
8.25
About LUCD
Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company's products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The Company is a subsidiary of PAVmed Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ford Reports 10.3% Decline in Q2 Vehicle Sales Amid Supply Issues
- Sales Decline: Ford reported a 10.3% year-over-year decline in U.S. new vehicle sales for Q2, totaling 549,200 units, primarily impacted by significant drops in F-Series pickups and a 40.7% fall in pure EV sales.
- F-Series Performance: While F-Series truck sales fell by 11%, Ford maintained its position as America's top-selling truck, with expectations for supply recovery in the second half of the year alleviating production delays caused by aluminum shortages.
- Market Share Changes: Ford's U.S. retail market share increased by 0.2 percentage points to 12.3% by the end of Q2, indicating enhanced competitiveness despite overall sales declines in the automotive sector.
- Industry Comparison: Ford's results slightly exceeded Cox Automotive's forecast of an 11.5% decline, reflecting a relatively stable performance amid broader market challenges faced by other automakers.
See More
Ten Years Post-Brexit: Economic Changes in the UK
- SpaceX Stock Volatility: Following its Nasdaq listing, SpaceX's stock fell 16% on Monday after announcing a computing power deal with AI startup Reflection and a $20 billion bond sale, resulting in a nearly 24% loss over three days, indicating waning investor confidence.
- U.S. Treasury Policy Update: Treasury Secretary Scott Bessent announced a 60-day authorization for Iranian oil production and sales, with Trump suggesting profits would fund U.S. agricultural purchases, though an Iranian banker denied any obligation, leading to a drop in oil prices on Monday.
- Target Leadership Crisis: Target's Executive Chairman Brian Cornell received only 87% support at the annual meeting, significantly below historical averages, raising concerns about his leadership amid profit and stock declines, as noted by analysts.
- Lucid Layoff Announcement: Lucid revealed plans to cut 18% of its U.S. workforce to reduce costs, aiming for annual savings of approximately $158 million, while also eliminating the operations chief position, reflecting a tightening strategy under market pressures.
See More
PAVmed Reports Business Expansion and Financial Update
- Financial Structure Optimization: PAVmed has simplified its capital structure and strengthened its balance sheet, enabling the company to focus on executing its core businesses and evaluate asset acquisition opportunities aligned with its long-term growth strategy, thereby laying a foundation for future expansion.
- Veris Health Progress: Veris Health continues to expand its commercial engagement with OSU-The James while advancing the FDA submission process for its implantable physiological monitor, which will enhance the company's market position in personalized cancer care.
- Lucid Diagnostics Momentum: Lucid Diagnostics has made significant progress in the commercialization of EsoGuard and strengthened its balance sheet ahead of upcoming Medicare coverage, which will support the company's future revenue growth.
- Medical Device Portfolio Relaunch: Under Joseph Virgilio's leadership, PAVmed is actively advancing its relaunched medical device portfolio while evaluating additional acquisition opportunities to enhance its market competitiveness and drive technological innovation.
See More
Lucid Diagnostics Q1 2026 Earnings Call Insights
- Testing Volume and Revenue: In Q1 2026, Lucid Diagnostics performed 3,177 EsoGuard tests, generating $1.3 million in revenue, indicating stable market demand despite a decrease from 3,664 tests in Q4 2025, which reflects the company's ability to maintain performance within its target range.
- Financing and Liquidity: The company strengthened its balance sheet with an underwritten public offering that raised approximately $16.8 million, resulting in a cash balance of $27.9 million as of March 31, 2026, and pro forma cash of $44.8 million, ensuring operational continuity and extending its runway into 2027.
- Healthcare Policy Progress: Management expressed optimism regarding the Medicare local coverage determination (LCD) despite delays, anticipating a draft publication soon, and has secured its first coverage policy with a laboratory benefit manager, expected to be made public in the coming weeks, which could drive revenue growth.
- Cost Control Measures: The average burn rate for Q1 was $12.1 million, slightly above the previous four-quarter average, yet the non-GAAP net loss per share improved to $0.07, better by $0.03 compared to the prior three quarters, demonstrating the company's efforts and effectiveness in managing operating expenses.
See More
Lucid Diagnostics Q1 Earnings Report Analysis
- Disappointing Earnings: Lucid Diagnostics reported a Q1 non-GAAP EPS of -$0.07, missing expectations by $0.01, indicating ongoing challenges in profitability that may affect investor confidence.
- Weak Revenue Growth: Despite a 51.8% year-over-year revenue increase to $1.26M, the figure fell short of expectations by $0.52M, suggesting competitive pressures that could impact future cash inflows.
- Cash Flow Concerns: As of March 31, 2026, Lucid's cash and cash equivalents stood at $27.9M, down from $34.7M on December 31, 2025, reflecting financial strain in operations and expansion efforts.
- Market Expansion Signals: Lucid Diagnostics announced expanded access in the VA market and achieved a 29% sequential growth in test volumes, indicating potential wins in Medicare and commercial payer markets that could lay the groundwork for future growth.
See More
Uber's Q1 Earnings Miss Estimates but Guidance Surpasses Expectations
- Earnings Performance: Uber reported Q1 revenue of $13.2 billion, missing the market expectation of $13.29 billion, with earnings per share at 13 cents, significantly below the expected 70 cents, indicating challenges in a complex macro environment.
- Net Income Decline: Due to the revaluation of equity investments, Uber's net income fell from $1.78 billion a year ago to $263 million, reflecting the pressure of market volatility on the company's profitability.
- Delivery Segment Growth: Uber's delivery segment achieved a 34% revenue growth to $5.07 billion, surpassing analyst expectations of $4.89 billion, demonstrating strong performance in Australia, Japan, and the UK.
- Optimistic Future Guidance: Uber expects total bookings for Q2 to range between $56.25 billion and $57.75 billion, exceeding the consensus estimate of $56.17 billion, indicating a positive outlook for future growth.
See More
Ford Reports 10.3% Decline in Q2 Vehicle Sales Amid Supply Issues
- Sales Decline: Ford reported a 10.3% year-over-year decline in U.S. new vehicle sales for Q2, totaling 549,200 units, primarily impacted by significant drops in F-Series pickups and a 40.7% fall in pure EV sales.
- F-Series Performance: While F-Series truck sales fell by 11%, Ford maintained its position as America's top-selling truck, with expectations for supply recovery in the second half of the year alleviating production delays caused by aluminum shortages.
- Market Share Changes: Ford's U.S. retail market share increased by 0.2 percentage points to 12.3% by the end of Q2, indicating enhanced competitiveness despite overall sales declines in the automotive sector.
- Industry Comparison: Ford's results slightly exceeded Cox Automotive's forecast of an 11.5% decline, reflecting a relatively stable performance amid broader market challenges faced by other automakers.
See More
Ten Years Post-Brexit: Economic Changes in the UK
- SpaceX Stock Volatility: Following its Nasdaq listing, SpaceX's stock fell 16% on Monday after announcing a computing power deal with AI startup Reflection and a $20 billion bond sale, resulting in a nearly 24% loss over three days, indicating waning investor confidence.
- U.S. Treasury Policy Update: Treasury Secretary Scott Bessent announced a 60-day authorization for Iranian oil production and sales, with Trump suggesting profits would fund U.S. agricultural purchases, though an Iranian banker denied any obligation, leading to a drop in oil prices on Monday.
- Target Leadership Crisis: Target's Executive Chairman Brian Cornell received only 87% support at the annual meeting, significantly below historical averages, raising concerns about his leadership amid profit and stock declines, as noted by analysts.
- Lucid Layoff Announcement: Lucid revealed plans to cut 18% of its U.S. workforce to reduce costs, aiming for annual savings of approximately $158 million, while also eliminating the operations chief position, reflecting a tightening strategy under market pressures.
See More
PAVmed Reports Business Expansion and Financial Update
- Financial Structure Optimization: PAVmed has simplified its capital structure and strengthened its balance sheet, enabling the company to focus on executing its core businesses and evaluate asset acquisition opportunities aligned with its long-term growth strategy, thereby laying a foundation for future expansion.
- Veris Health Progress: Veris Health continues to expand its commercial engagement with OSU-The James while advancing the FDA submission process for its implantable physiological monitor, which will enhance the company's market position in personalized cancer care.
- Lucid Diagnostics Momentum: Lucid Diagnostics has made significant progress in the commercialization of EsoGuard and strengthened its balance sheet ahead of upcoming Medicare coverage, which will support the company's future revenue growth.
- Medical Device Portfolio Relaunch: Under Joseph Virgilio's leadership, PAVmed is actively advancing its relaunched medical device portfolio while evaluating additional acquisition opportunities to enhance its market competitiveness and drive technological innovation.
See More
Lucid Diagnostics Q1 2026 Earnings Call Insights
- Testing Volume and Revenue: In Q1 2026, Lucid Diagnostics performed 3,177 EsoGuard tests, generating $1.3 million in revenue, indicating stable market demand despite a decrease from 3,664 tests in Q4 2025, which reflects the company's ability to maintain performance within its target range.
- Financing and Liquidity: The company strengthened its balance sheet with an underwritten public offering that raised approximately $16.8 million, resulting in a cash balance of $27.9 million as of March 31, 2026, and pro forma cash of $44.8 million, ensuring operational continuity and extending its runway into 2027.
- Healthcare Policy Progress: Management expressed optimism regarding the Medicare local coverage determination (LCD) despite delays, anticipating a draft publication soon, and has secured its first coverage policy with a laboratory benefit manager, expected to be made public in the coming weeks, which could drive revenue growth.
- Cost Control Measures: The average burn rate for Q1 was $12.1 million, slightly above the previous four-quarter average, yet the non-GAAP net loss per share improved to $0.07, better by $0.03 compared to the prior three quarters, demonstrating the company's efforts and effectiveness in managing operating expenses.
See More
Lucid Diagnostics Q1 Earnings Report Analysis
- Disappointing Earnings: Lucid Diagnostics reported a Q1 non-GAAP EPS of -$0.07, missing expectations by $0.01, indicating ongoing challenges in profitability that may affect investor confidence.
- Weak Revenue Growth: Despite a 51.8% year-over-year revenue increase to $1.26M, the figure fell short of expectations by $0.52M, suggesting competitive pressures that could impact future cash inflows.
- Cash Flow Concerns: As of March 31, 2026, Lucid's cash and cash equivalents stood at $27.9M, down from $34.7M on December 31, 2025, reflecting financial strain in operations and expansion efforts.
- Market Expansion Signals: Lucid Diagnostics announced expanded access in the VA market and achieved a 29% sequential growth in test volumes, indicating potential wins in Medicare and commercial payer markets that could lay the groundwork for future growth.
See More
Uber's Q1 Earnings Miss Estimates but Guidance Surpasses Expectations
- Earnings Performance: Uber reported Q1 revenue of $13.2 billion, missing the market expectation of $13.29 billion, with earnings per share at 13 cents, significantly below the expected 70 cents, indicating challenges in a complex macro environment.
- Net Income Decline: Due to the revaluation of equity investments, Uber's net income fell from $1.78 billion a year ago to $263 million, reflecting the pressure of market volatility on the company's profitability.
- Delivery Segment Growth: Uber's delivery segment achieved a 34% revenue growth to $5.07 billion, surpassing analyst expectations of $4.89 billion, demonstrating strong performance in Australia, Japan, and the UK.
- Optimistic Future Guidance: Uber expects total bookings for Q2 to range between $56.25 billion and $57.75 billion, exceeding the consensus estimate of $56.17 billion, indicating a positive outlook for future growth.
See More
